Cargando…

Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival

BACKGROUND: Guidelines do not recommend surgery for patients with oligometastatic disease from esophagogastric adenocarcinoma (EGAC), although some studies suggest a more favorable survival. We analyzed the outcome of oligometastatic EGAC receiving FLOT chemotherapy followed by surgery. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Runkel, Mira, Verst, Rasmus, Spiegelberg, Julia, Fichtner-Feigl, Stefan, Hoeppner, Jens, Glatz, Torben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7805136/ https://www.ncbi.nlm.nih.gov/pubmed/33435947 http://dx.doi.org/10.1186/s12893-020-01035-9

Ejemplares similares

Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials
por: Glatz, Torben, et al.
Publicado: (2020)

Comparison of hyperthermic intraperitoneal chemotherapy regimens for treatment of peritoneal-metastasized colorectal cancer
por: Spiegelberg, Julia, et al.
Publicado: (2020)

ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
por: Hoeppner, Jens, et al.
Publicado: (2016)

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study
por: Nappo, Floriana, et al.
Publicado: (2023)

Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective
por: Sisic, Leila, et al.
Publicado: (2023)

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors
por: Franceschini, Davide, et al.
Publicado: (2023)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Severe hyperlactatemia in unselected surgical patients: retrospective analysis of prognostic outcome factors
por: Spiegelberg, Julia, et al.
Publicado: (2022)

Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal Treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction
por: Gebauer, Florian, et al.
Publicado: (2023)

Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
por: Lorenzen, S, et al.
Publicado: (2013)

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO
por: Götze, Thorsten O., et al.
Publicado: (2021)

Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
por: Laxague, Francisco, et al.
Publicado: (2021)

Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma
por: Stüben, Björn-Ole, et al.
Publicado: (2022)

Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
por: Zeng, Hanqing, et al.
Publicado: (2022)

ASO Author Reflections: Role of Local Treatment for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers
por: Bhargava, Prabhat, et al.
Publicado: (2022)

Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Cancer-associated Macrophage-like Cells in Patients with Non-metastatic Adenocarcinoma of the Esophagus - Cytomorphological Heterogeneity
por: Braun, Clara, et al.
Publicado: (2023)

Ligamentum teres augmentation (LTA) for hiatal hernia repair after minimally invasive esophageal resection: a new use for an old structure
por: Runkel, Mira, et al.
Publicado: (2021)

Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
por: Kroese, Tiuri E., et al.
Publicado: (2022)

Se maintenir à flot
por: Auer, Rebecca Ann C.
Publicado: (2021)

Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
por: Moussa, Osama, et al.
Publicado: (2022)

Repair of a Grynfeltt-Lesshaft hernia with the PROCEED™ VENTRAL PATCH: a case report
por: Glatz, Torben, et al.
Publicado: (2018)

Postoperative Hiatal Hernia after Ivor Lewis Esophagectomy—A Growing Problem in the Age of Minimally Invasive Surgery
por: Kuvendjiska, Jasmina, et al.
Publicado: (2023)

Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma
por: GÜRLER, Fatih, et al.
Publicado: (2022)

Un flot ininterrompu de données
por: Ourghanlian, Bernard
Publicado: (2006)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
por: Tong, Gangling, et al.
Publicado: (2020)

Hybrid Minimally Invasive Esophagectomy–Surgical Technique and Results
por: Kuvendjiska, Jasmina, et al.
Publicado: (2019)

Robotic-Assisted Surgery for Primary Hepatobiliary Tumors—Possibilities and Limitations
por: Spiegelberg, Julia, et al.
Publicado: (2022)

Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives
por: Martini, Verena, et al.
Publicado: (2019)

Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT
por: Melekoglu, Ebru, et al.
Publicado: (2023)

Results of the observational prospective RealFLOT study
por: Giommoni, Elisa, et al.
Publicado: (2021)

The roles of FLOT1 in human diseases (Review)
por: Zhan, Ziqing, et al.
Publicado: (2023)

Internet-based perioperative exercise program in patients with Barrett’s carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial
por: Pfirrmann, Daniel, et al.
Publicado: (2017)

Current surgical treatment of esophagogastric junction adenocarcinoma
por: Zhang, Shun, et al.
Publicado: (2019)

Integrative proteomic characterization of adenocarcinoma of esophagogastric junction
por: Li, Shengli, et al.
Publicado: (2023)

Postoperative fluid overload is a risk factor for adverse surgical outcome in patients undergoing esophagectomy for esophageal cancer: a retrospective study in 335 patients
por: Glatz, Torben, et al.
Publicado: (2017)

Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)
por: EROL, Cihan, et al.
Publicado: (2022)

Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis
por: SCHULZE, BJÖRN, et al.
Publicado: (2014)

Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety
por: Villanueva, Luis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d0lh06j514u3brlqm57u60p9nd